Muloc, Daelyn C.

HRN: 12-37-30  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/27/2022
CO-AMOXICLAV 457MG/5ML, 70ML SUSPENSION (BOT)
07/27/2022
08/03/2022
PO
3.5ml
BID
Multiple Soft Tissue Injuries
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: